Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials

Traders Union
All News
Business & Wealth
Companies
Webinar drives Rett trial progress

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

27.08.2026

Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials — Webinar drives Rett trial progress

Taysha Gene Therapies, Inc. is promoting a webinar hosted by the Child Neurology Society featuring Dr. Arthur Partikian, a leading expert in Rett syndrome.

The session is set to explore how natural history research is shaping more patient-centered clinical trials, refining treatment expectations, and preparing the Rett syndrome community for emerging therapies. The event reflects a growing emphasis on integrating scientific insights with direct clinical application for rare disease communities.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier this year, Taysha Gene Therapies secured a commercial supply agreement with Catalent for TSHA-102, marking a step in advancing its pipeline through new manufacturing partnerships. The company’s shares rose 6.7% to $6.17 following the announcement of its upcoming second quarter 2026 earnings and corporate update earlier this month. These developments come as Taysha continues to engage clinical and patient communities in the rare disease space.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Who is Richard Heart, the HEX founder wanted by Interpol?

By Olena Litvinenko
15 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Editors' Picks

Kaiko CEO: European stablecoins still cannot compete with USDT

By Eugene Komchuk
17 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Editors' Picks

Adobe and AI: Is the creative software giant losing its edge?

By Dmytro Kharkov
20 hours ago

Adobe and AI: Is the creative software giant losing its edge?

Editors' Picks

All Editors' Top Picks

Latest Taysha News

Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event

By Hanna Syniavska
15.10.2026

Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event

Companies

TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting

By Eugene Komchuk
01.10.2026

TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting

Companies

TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing

By Andrey Mastykin
11.08.2026

TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing

Companies

All Taysha News

Olena Litvinenko
15 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Eugene Komchuk
17 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Dmytro Kharkov
20 hours ago

Adobe and AI: Is the creative software giant losing its edge?

Pavlo Kot
Yesterday

Solana vs. Base: Who will dominate the token launch market?

Pavlo Kot
17.10.2026

Jobs in crypto: Which specialists are in demand now?

Mykhailo Ihnatenko
19 min ago

Charlie Bilello: Releases video on key market charts and themes

Hanna Syniavska
49 min ago

CLO CEF Dashboard launched for paid subscribers, Michael Kao writes

Mikhail Vnuchkov
1 hour ago

NVDA may resort to more drastic steps, Michael Taylor notes

Alena Volkova
1 hour ago

CoreWeave 2028–2030 EPS estimates seen 50%–70% below consensus, HSBC expects

Eugene Komchuk
1 hour ago

Jason Pizzino: Final phase of crypto bubble has started but challenges remain

Top News

Ivan Andriyenko
13 hours ago

Canada inflation comes in below forecasts ahead of central bank decision

Canada inflation comes in below forecasts ahead of central bank decision

Eugene Komchuk
13 hours ago

Trump family's stablecoin loses $400 million in market capitalization

Trump family's stablecoin loses $400 million in market capitalization

Olga Shendetskaya
15 hours ago

Indonesia tightens stock market rules to address MSCI concerns

Indonesia tightens stock market rules to address MSCI concerns

Eugene Komchuk
17 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Kaiko CEO: European stablecoins still cannot compete with USDT

Eugene Komchuk
18 hours ago

JPMorgan launches JPM Coin token on Ethereum

JPMorgan launches JPM Coin token on Ethereum

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

EUR/USD holds near 1.1230 as ECB and Fed expectations weigh on currency amid Treasury yield stability

Mykhailo Ihnatenko
Now

Nvidia stock tests $217 as AI infrastructure worries pressure tech sector

Parshwa Turakhiya
Now

Crypto.com and Novig challenge Missouri sports betting restrictions

Igor Krasulya
Now

French bond yields face pressure as unrest threatens budget plans

Mykhailo Ihnatenko
Now

Ethereum price prediction: Can ETH break $2,440 before another liquidation wave?

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.